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6 years (range, 2–24 years). The majority were Lucarelli class III
(56%), with 38% class II and 6% class I. Median cell dose was
4.4  108 nucleated cells/kg (range, 2.1–19.7). Acute GVHD was
seen in 79 patients (51.9%) at a median time of 22.8 days (range,
7–96) after bone marrow transplantation. Grade I GVHD was seen
in 24%; grade II-IV GVHD, in 76%; grade III–IV GVHD, in
29%. Skin was involved in 69 patients (87.3%); the gastrointestinal
(GI) tract, in 38 (48%); and the liver, in 26 (32.9%). Eight patients
(10.1%) expired due to either progressive GVHD or cytomegalo-
virus infection infection, whereas the mortality rate in patients with
grade IV GVHDwas 25%. Of the evaluable 115 patients, 28 (24%)
developed chronic GVHD, which was limited in 25 (89.2%) and
extensive in 3 (10.8%). The skin was involved in 50% of the
patients, the GI tract in 64.2%, and the liver in 21%, with pulmo-
nary GVHD in 1 patient. GVHD-related mortality was seen in 2
patients (7.1%). No risk factors, including patient age, donor age,
sex mismatch, Lucarelli class, conditioning regimen, cell dose,
bacterial infections, VOD, and doses of MTx given were identiﬁed.
Reduction in the MTx dose from 15 to 10 mg/m2 did not increase
the risk of acute GVHD. In patients with acute GVHD, female to
male donor sex mismatch and cyclosporine-alone prophylaxis were
associated with an increased risk of developing grade III or IV
GVHD. The only risk factor identiﬁed for chronic GVHD was
acute GVHD. At median follow-up of 50 months (range, 3–145
months), 73.4% of patients with GVHD and 72.6% of patients
without GVHD were alive. GVHD is a major problem in patients
undergoing allogeneic BMT for thalassemia, although it is not
associated with increased mortality or secondary graft rejection.
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SEQUENTIAL BLOCKADE AND ENGAGEMENT OF COSTIMULATORY
PATHWAYS: A POTENTIAL STRATEGY FOR AMPLIFYING GRAFT-VER-
SUS-LEUKEMIA RESPONSES WITHOUT GRAFT-VERSUS-HOST DISEASE
Chakraverty, R.1; Buchli, J.1; Zhao, G.1; Hsu, R.1; Croft, M.2; Sykes,
M.1 1. Transplantation Biology Research Center, Massachusetts General
Hospital, Boston, MA; 2. La Jolla Institute for Allergy and Immunology,
San Diego, CA.
One potential approach for the effective disengagement of graft-
versus-leukemia (GVL) effects from graft-versus-host disease
(GVHD) after bone marrow transplantation (BMT) is the use of
nonmyeloablative (NM) conditioning to induce mixed chimerism
as a platform for the delayed transfer of donor T cells. In preclin-
ical models, CD8 T cells derived from donor leucocyte infusions
(DLIs) can induce powerful responses against tumors of host ori-
gin, but the effect lacks durability such that a rechallenge with
tumor inevitability leads to tumor progression and death. This
deﬁcit is associated with the failure of functional CD8 effector/
memory T cells (TE/M) to survive long-term post-DLI. We rea-
soned that strategies that augment the survival of GVH TE/M
might enhance the durability of the GVL response and, in the
absence of tissue inﬂammation induced by conditioning, might not
induce GVHD. One potential strategy is costimulation through
the tumor necrosis family receptor, OX40, which is expressed on
activated T cells, is antiapoptotic, and enhances recruitment of
TE/M to the memory pool. To test the feasibility of this approach,
we ﬁrst established mixed hematopoietic chimeras (MCs) in
B6D2F1 recipients using an NM protocol (3 Gy TBI intraperito-
neal injections of anti-CD154 and anti-CD8 monoclonal antibody
(mAb) on day 0), followed by infusion of 2  107 C57BL/6 bone
marrow cells. Ten weeks later, after the mAb had cleared from the
circulation, MC received DLI followed 2–5 days later by intraperi-
toneal injection of agonistic OX40 or control mAb. Administration
of OX40 mAb was associated with more rapid and more consistent
conversion to full donor chimerism induction as compared with
control mAb. By administering DLI that included CD8 T cells
from 2C transgenic mice that bear T-cell receptors speciﬁc for
recipient class I major histocompatibility complex Ld, we observed
that OX40 costimulation was associated with marked increases in
the numbers of 2C CD8 T cells in spleen, blood, lymph node,
and bone marrow and increased intracellular expression of inter-
feron-. By day 60 post-DLI, antihost CTL activity was clearly
detectable in anti-OX40 recipients but not in controls. Impor-
tantly, the enhancement of the magnitude and durability of the
GVH reaction could be achieved without the induction of signif-
icant clinical or histological GVHD. We conclude that OX40
costimulation after delayed DLI to established MC represents a
potential means of enhancing the magnitude and duration of a
GVH reaction, and hence GVL, without the induction of signiﬁ-
cant GVHD.
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CLONAL EXPANSION BUT IMPAIRED TRAFFICKING OF GVH-REACTIVE
T CELLS FOLLOWING DELAYED DLI TO MIXED CHIMERAS
Chakraverty, R.1; Buchli, J.1; Zao, G.1; Lin, C.; Sykes, M.1 1. Trans-
plantation Biology Research Center, Massachusetts General Hospital,
Boston, MA; 2. Wellman Center for Photomedicine, Massachusetts Gen-
eral Hospital, Boston, MA.
Donor leucocyte infusions (DLI) given to established mixed
chimeras (MCs) can eliminate normal and malignant hematopoi-
etic cells without causing graft-versus-host disease (GVHD). DLI
given immediately after lethal irradiation leads to severe GVHD.
We examined the expansion, differentiation, and in vivo trafﬁcking
of GVH-reactive T cells after delayed DLI and compared these
outcomes when identical DLI was administered early after lethal
irradiation (TBI). C57BL/6 (B6) CD45.2  BALB/c 3 BALB/c
MC were prepared by TBI of BALB/c recipients and reconstitu-
tion with T-cell depleted bone marrow (TCD BM) derived from
donor and recipient strains. Ten weeks later, 107 CD45.1 B6 and
5 106 2C transgenic splenocytes were transferred. CD8 T cells
from 2C transgenic mice bear TCR speciﬁc for recipient class I
MHC Ld and can be detected using a clonotypic marker. For
comparison, identical DLI together with TCD BM was adminis-
tered to freshly irradiated BALB/c or B6 CD45.2 syngeneic recip-
ients. After delayed DLI, expansion of donor CD4 cells (on peak
day 10) preceded expansion of CD8 cells (on peak day 13) in the
spleen, with less accumulation in the lymph nodes, BM, liver and
lung, and no accumulation in the gut. In contrast, the kinetics of
donor T-cell expansion were more rapid in freshly irradiated re-
cipients with T cell responses peaking on day 4–7. Major trafﬁck-
ing of donor T cells to the gut was observed. After delayed DLI,
the kinetics of 2C CD8 T cell expansion were similar to those of
the polyclonal CD8 T-cell population. 2C CD8 T cells ac-
quired a memory/activation phenotype (CD44hi, CD45RBlo,
CD62Llo, CD49d, CD27, 47high) to a similar extent as
those in TBI mice developing GVHD. In additional experiments,
we transferred 4  106 B6 GFP T cells to freshly irradiated B6
xDBA/2 (B6D2F1) or B63B6D2F1 established MC and imaged
trafﬁcking to skin in real time by 2-photon imaging of postcapillary
venules of recipient ear pinnae. By day 5, we observed marked
rolling, tethering/adhesion, and extravasation of GFP T-cells in
freshly irradiated recipients. In contrast, GFP T cells failed to
trafﬁc to the skin on day 5 or 12 after transfer to established MC
despite their presence within the peripheral blood. Thus, in con-
trast to the response in freshly irradiated mice that develop
GVHD, GVH reactions induced by delayed DLI are characterized
by similar clonal expansion but failure of GVH-reactive T cells to
trafﬁc to the skin or the gut.
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RITUXAN FOR STEROID-REFRACTORY CHRONIC GVHD
Cutler, C.1; Miklos, D.2; Lee, S.J.1; Woo, S.-B.1; Treister, N.1; Bien-
fang, D.1; Klickstein, L.1; Levin, J.1; Windawi, S.1; Pasek, M.1; Ho,
V.1; Ritz, J.1; Antin, J.1; Soiffer, R.1; Alyea, E.1 1. Dana Farber Cancer
Institute and Brigham and Women’s Hospital, Harvard Medical School,
Boston, MA; 2. Stanford University School of Medicine, Stanford, CA.
Donor-derived T cells are thought to be the primary effectors of
chronic graft-versus-host disease (cGVHD); however, additional
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mechanisms of tissue injury may exist. Antibodies against minor
histocompatibility antigens develop in association with cGVHD,
suggesting a role for B cells. We therefore began a clinical trial of
speciﬁc anti-B-cell therapy with rituxan for steroid-refractory
cGVHD. Methods: Subjects had steroid-refractory ( 0.5 mg/kg
prednisone each day for 4 weeks), clinically extensive cGVHD on
stable doses of immunosuppressants. Rituxan (375 mg/m2/week 
4) was followed by a second course for nonresponders or partial
responders 4 weeks later. All patients underwent thorough oral,
ocular, rheumatologic, and dermatologic examinations by subspe-
cialists before and 8 weeks after rituxan therapy. A validated symp-
tom scale was administered before and after rituxan therapy. Re-
sults: 16 patients (median age, 42.5 years) were treated, 15 of
whom were on steroids (4 alone, 7 with 1 immunosuppresant, and
4 with 2 immunosuppressants). One patient was on tacrolimus
alone. End-organ involvement included skin (in 13 patients), eye
(in 8 patients), musculoskeletal (in 8 patients), and oral mucosa (in
5 patients). Six patients received 1 and 10 patients received 2
4-week courses of rituxan at a mean of 13.7 months (range, 2.9–82
months) from cGVHD diagnosis and 24.6 months from transplan-
tation (range, 8.5–114.6 months). There were 5 grade 3 adverse
events (3 cases of gastroenteritis, 1 case of hepatitis B reactivation,
and 1 case of conjunctivitis) and 1 infusion reaction. Eight weeks
after starting rituxan, CD19 B cells were undetectable in all
peripheral blood samples, median serum IgG levels fell by 19.8%,
and IgM levels fell by 33%. Median follow-up was 160 days.
Objective responses were noted in 10 patients (62.5%, all skin/
musculoskeletal responses), and one patient had progressive cuta-
neous cGVHD. There was 1 cGVHD ﬂare after a partial response
and 1 malignant relapse. The median reduction in clinical cutane-
ous involvement was 52%, and the median reduction in the rheu-
matologic VAS pain score was 87.5%. Mean symptom scores
improved in 7 patients (6 of whom had clinical responses), were
unchanged in 7 patients, and worsened in 2 patients. As a result of
cGVHD responses, prednisone doses were decreased in 11 patients
and unchanged in 4 patients (median dose reduction, 50%). At this
time, all patients remain on systemic immunosuppression. Con-
clusions: Rituxan is safe in patients with cGVHD and is active
against cutaneous and musculoskeletal cGVHD. B-cell immunity
contributes to at least some of the clinical manifestations of
cGVHD.
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HYPERACUTE GVHD: ANALYSIS OF RISK FACTORS, CLINICAL MANIFES-
TATIONS, AND OUTCOMES
Couriel, D.R.; Saliba, R.; De Lima, M.J.; Hosing, C.; Andersson, B.; De
Jesus, J.; Mickler, K.; Hsu, Y.; Shpall, E.J.; Neumann, J.; Ghosh, S.;
Champlin, R. University of Texas M.D. Anderson Cancer Center,
Houston, TX.
We evaluated the clinical characteristics and risk factors for
hyperacute graft-versus-host disease (GVHD) in 815 consecutive
patients transplanted at M.D. Anderson Cancer Center between
January 1998 and September 2002. Our deﬁnition of hyperacute
GVHD included all patients with a diagnosis of GVHD within 14
days after allogeneic bone marrow or peripheral blood stem cell
transplantation (PSCT). Of 381 patients presenting with clinical
evidence of acute GVHD, 22% (n  83) occurred within 14 days
posttransplantation (early GVHD), and were all biopsy-proven.
Grade I GVHD occurred in 12% of these patients, grade II in
53%, grade III in 13%, and grade IV in 22%. The proportion of
grade II-IV GVHD in this group was signiﬁcantly higher (88%)
than in the 298 patients presenting with GVHD between days 15
and 100 posttransplantation (64%) (P  .001). The majority of
patients with early GVHD had skin involvement (89%), followed
by gastrointestinal (43%), and liver GVHD (19%). Skin involve-
ment was signiﬁcantly more common (89% vs 76%; P  .01), and
more severe (stage III or IV 63% vs 32%; P  .001) in the early
GVHD group. Signiﬁcantly factors on univariate analysis included
a graft from a mismatched (MM) related donor (HR  4.4; P 
.001) or a matched unrelated donor (MUD) (HR  2.4; P .001)
vs a graft from a matched related donor, and myeloablative pre-
parative regimen with or without total body irradiation (HR 2.5;
P  .001). These effects remained signiﬁcant when evaluated in a
multivariate model. Donor’s age  40 years was associated with a
marginally signiﬁcant lower rate of early GVHD (HR  0.6; P 
.05), and there was a trend toward increased rates for patients
receiving sex-mismatched grafts, patients transplanted for solid
tumors, and those having received more than 5 chemotherapy
regimens before transplantation. There was no difference in the
distribution of CD34 or CD3 cells infused. All-cause mortality
rate was signiﬁcantly higher within 6 months posttransplantation
for patients with early GVHD (HR  2.2; P  .001) compared
with all other patients or to patients developing acute GVHD after
day 14 (HR  1.6; P  .009). Acute GVHD death rate was also
signiﬁcantly higher (HR  2.3; P  .007). Hyperacute GVHD
occurs in a substantial proportion of patients undergoing HSC
transplant, even before neutrophil engraftment. Skin involvement,
grades 3–4 GVHD, and higher mortality are common features of
this syndrome.
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ASSESSING DONOR CHIMERISM LEVEL AMONG CD3 T, CD4 T, CD8 T,
AND NK CELLS PREDICTS SUBSEQUENT GRAFT REJECTION, GVHD,
AND RELAPSE AFTER ALLOGENEIC HCT WITH NONMYELOABLATIVE
CONDITIONING
Baron, F.1; Storb, R.1; Gooley, T.1; Sandmaier, B.1; Gisburne, S.1; Shin,
S.1; Stroup, P.1; Baker, J.1; Maris, M.1; Maloney, D.1; Heimfeld, S.1;
Grumet, F.C.2; Chauncey, T.1; Blume, K.2; Little, M.T.1 1. Fred
Hutchinson Cancer Research Center, Seattle, WA; 2. Stanford Univer-
sity, Stanford, CA.
We previously showed that low levels of day-14 CD3 T and NK
(CD56) cells donor chimerism predicted graft rejection, whereas
high levels of day-28 CD3 T-cell donor chimerism predicted acute
graft-versus-host disease (GVHD) after HCT with nonmyeloab-
lative conditioning. Here we investigate whether assessing chimer-
ism levels among CD4 T cells and CD8 T cells, and also the
absolute number of lymphocyte subsets of donor and host origins,
would lend greater precision to our initial observations. We ana-
lyzed data from 157 patients receiving HCT after conditioning
with 2 Gy TBI / ﬂudarabine as treatment for AML (n  22),
ALL (n  4), CML (n  13), CLL (n  19), MDS (n  26), MM
(n  24), NHL (n  30), HD (n  14), RCC (n  4), and WASP
deﬁciency (n  1). Postgrafting immunosuppression included
MMF and CSP. A total of 97 patients received grafts from HLA-
identical siblings, and 60 patients received grafts from HLA-
matched unrelated donors. Lymphocyte subsets were isolated from
peripheral blood by ﬂow cytometry on days 14, 28, and 42. The
proportion of cells of donor origin (chimerism levels) were assessed
by VNTR-PCR and quantiﬁed by phosphor imaging. Eighteen
patients (11%) had graft rejection. Day-14 donor chimerism lev-
els  50% among CD3 T (P .0007), CD4 T (P .03), and NK
cells (P.003) but not CD8 T cells predicted graft rejection. High
absolute numbers of CD3 T (P .002) and NK cells (P  .002) of
host origin on day 14 were each associated with increased risks of
graft rejection when treated as continuous linear variables. Grades
2, 3, and 4 acute GVHD were seen in 40%, 9%, and 5% of
patients, respectively. High donor chimerism levels on day 14
among CD3 T (P  .02), CD4 T (P .03), and CD8 T cells (P
.02) but not NK cells were each associated with increased risks of
grades 2–4 acute GVHD. High absolute numbers of CD4 T (P
.04) and CD8 T cells (P .04) of donor origin on days 14–42
were each associated with increased risks of grade 2–4 acute
GVHD when treated as continuous linear variables, whereas high
donor CD3 T (P  .002), CD8 T (P  .006), and NK cell (P 
.002) chimerism levels from days 14–42 were associated with
decreased risks of relapse. No statistically signiﬁcant correlations
between absolute numbers of donor cells and risks of relapse were
found. These data suggest that assessing CD3, CD4, CD8, and NK
cell donor chimerism levels and determining absolute numbers of
CD3 and NK cells of host and donor origins are useful for pre-
dicting HCT outcomes after nonmyeloablative conditioning.
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